Loading

Azafaros B.V.

June 16, 2025
Company Presentation
Brain Health
Azafaros, founded in 2018, is a clinical-stage company addressing lysosomal storage disorders, including GM1 and GM2 gangliosidoses and Niemann-Pick type C. With roots in discoveries from Leiden University and Amsterdam UMC, and led by a team of industry veterans, Azafaros is committed to delivering disease-modifying therapies for rare genetic diseases. Poised to start a global Phase III clinical trial for its lead asset, Azafaros is achieving a key milestone in its mission to bring innovative treatments to patients and families affected by devastating disorders. By leveraging its scientific expertise, extensive network, and innovative mindset, the company challenges conventional pathways to accelerate the development of life-changing therapies. Backed by leading investors such as Forbion, BioGeneration Ventures, BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital, Azafaros is uniquely positioned to make a significant impact on rare disease treatment worldwide.
Azafaros B.V.
Company HQ City: DC Naarden
Company HQ Country: Netherlands
Year Founded: 2018
Lead Product in Development: Nizubaglustat

CEO

Stefano Portolano

Year Founded

2018

Development Phase of Lead Product

Phase II

When you expect your next catalyst update?

$100M+ Series B near closing, with plans to initiate two Phase III trials across three indications.

What is your next catalyst (value inflection) update?

Mid Q2 2025

Website

https://www.azafaros.com/about-us
Primary Speaker
Stefano Portolano
Stefano Portolano
Dr Stefano Portolano
Azafaros

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS